TL;DR
This study reveals a critical communication pathway in glioma where tumor-derived lactate signals to macrophages (TAMs) via the GPR65 receptor. This interaction triggers TAMs to release HMGB1, a protein that fuels glioma progression. Blocking this lactate-GPR65-HMGB1 axis shows promise as a therapeutic strategy for glioblastoma.
What Problem Does This Paper Address?
Glioma, particularly glioblastoma (GBM), is a highly aggressive brain tumor with poor patient outcomes. While the tumor microenvironment (TME) plays a crucial role in its progression, the precise mechanisms by which tumor cells and immune cells like tumor-associated macrophages (TAMs) interact remain poorly understood. Specifically, how lactate, a metabolic byproduct of rapidly growing tumor cells, influences TAM behavior and promotes glioma progression was unclear. This paper aims to unravel this complex interplay, focusing on the signaling pathways involved and identifying potential therapeutic targets.
Methods
The researchers employed a multi-faceted approach:
- Bioinformatics Analysis: They analyzed public datasets (TCGA, CGGA) and single-cell RNA-seq data to identify gene expression patterns and cell distributions related to lactate metabolism and TAM markers in glioma.
- In Vitro Assays:
- Cell Proliferation and Viability: CCK8 and colony formation assays were used to measure how treatments affected tumor cell growth.
- Cell Migration and Invasion: Wound healing and Transwell assays were utilized to assess the ability of tumor cells to move and penetrate tissues.
- Molecular Analysis: Western blotting and RT-PCR were used to detect protein and mRNA expression levels of key molecules. Immunofluorescence staining visualized protein localization within cells and tissues.
- Signaling Pathway Investigation: They used specific inhibitors and activators to probe the cAMP/PKA/CREB pathway and measured intracellular cAMP levels.
- In Vivo Models: Subcutaneous and orthotopic xenograft tumor models in mice were established to evaluate the therapeutic efficacy of targeting GPR65 or HMGB1.
Datasets
The study utilized publicly available datasets:
- The Cancer Genome Atlas (TCGA): A large-scale cancer genomics database.
- The Chinese Glioma Genome Atlas (CGGA): Another comprehensive resource for glioma genomic data.
- UCSC Cell Browser and Single Cell Portal (GSE131928): These platforms provided single-cell RNA-seq data for analyzing cell-type specific gene expression in GBM.
Key Insights and Ideas
- Lactate as a "Danger Signal" for TAMs: The study highlights that lactate, beyond being a metabolic waste product, acts as a crucial signaling molecule that actively reprograms TAMs.
- GPR65 as the Lactate Sensor on TAMs: A key finding is the identification of GPR65, a proton-sensing receptor, as the primary sensor for lactate on TAMs in the glioma TME. This receptor is selectively upregulated on TAMs in glioma.
- The cAMP/PKA/CREB Cascade: The research elucidates a specific intracellular signaling pathway (cAMP/PKA/CREB) that is activated by lactate binding to GPR65 on TAMs.
- HMGB1 as the Effector Molecule: Activation of the cAMP/PKA/CREB pathway leads to the secretion of HMGB1 by TAMs. HMGB1, in turn, promotes glioma cell proliferation, migration, and invasion.
- A Vicious Cycle: The study uncovers a feedback loop where tumor cells produce lactate, which activates TAMs via GPR65 to release HMGB1, further enhancing glioma progression.
Key Results
- Elevated Lactate Metabolism in Glioma: Glioma tissues showed increased expression of lactate-producing (LDHA) and lactate-transporting (MCT1) molecules, correlating with higher tumor grade and poorer survival.
- Lactate Induces M2 TAM Polarization: Tumor-derived lactate in conditioned media (CM) from glioma cells induced TAMs to adopt an M2-polarized phenotype, characterized by specific marker expression and morphology changes.
- M2 TAMs Promote Glioma Progression: CM from lactate-stimulated M2 TAMs significantly enhanced glioma cell proliferation, migration, and invasion, and promoted mesenchymal transition.
- GPR65 is Crucial for Lactate Signaling: Knockdown of GPR65 on TAMs attenuated the pro-tumorigenic effects of lactate-stimulated TAMs on glioma cells.
- HMGB1 is the Key Mediator: HMGB1 secretion by TAMs was found to be essential for lactate-induced glioma progression. Supplementing with recombinant HMGB1 rescued the effects of GPR65 silencing, while inhibiting HMGB1 reduced tumor growth.
- In Vivo Efficacy: Inhibiting GPR65 or HMGB1 in mouse models significantly reduced tumor growth and improved survival, demonstrating the therapeutic potential of targeting this pathway.
Limitations and Future Work
- In Vivo Models: While the study used both subcutaneous and orthotopic models, the authors acknowledge that further validation in more complex and clinically relevant models might be beneficial.
- Selective GPR65 Inhibitors: The paper notes that while targeting GPR65 shows promise, selective inhibitors are still under development, suggesting this as a future research direction.
- HMGB1 Mechanisms: The authors mention that while HMGB1's role in inflammation and tumor progression is established, its exact mechanisms in cancer require further investigation.
- Broader TME Interactions: The study focuses on the lactate-TAM-glioma cell axis. Future work could explore how this pathway interacts with other components of the TME, such as other immune cells or the extracellular matrix.
Summary updated